New drug cocktail targets rare, aggressive cancer

This phase 2 trial is testing whether combining two chemotherapy drugs—Abraxane and liposomal doxorubicin—can shrink tumors in people with advanced or unresectable angiosarcoma, a rare and aggressive cancer of blood vessels. The study will enroll 69 patients who have already tried standard treatments. Participants receive the drug combination intravenously every three weeks for up to eight cycles, and researchers will measure how many patients respond to treatment.